Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Marcelo C. Pasquini, et al.
Despite a larger proportion of older patients, patients with transformed or double-hit lymphoma, and patients with a worse performance status, best responses and toxicities are comparable to those reported for the ZUMA-1 trial
